Soluble intercellular adhesion molecule-1 in patients with chronic hepatitis C treated with interferon

A. M. Sonnante, R. Cozzolongo, G. De Michele, R. Cuppone, O. G. Manghisi, M. Quaranta

Research output: Contribution to journalArticlepeer-review

Abstract

Background. High levels of intercellular adhesion molecule-1 (ICAM-1) have been reported both on hepatocytes and in serum of patients with chronic liver diseases. During interferon therapy, a reduction of intrahepatic expression of ICAM-1 has been shown. Little is known about the effect of this drug on ICAM-1 serum levels (sICAM-1). Methods. We evaluated sICAM-1 levels before, during and after interferon treatment in 22 patients with type C chronic hepatitis or cirrhosis. We also studied nine healthy subjects as control group. Results. Statistically significant higher levels of sICAM-1 were shown in patients with liver disease compared to the controls. The ICAM-1 baseline levels were similar in patients with chronic hepatitis or cirrhosis but, during therapy, the sICAM-1 level significantly decreased only in patients with chronic hepatitis. After withdrawal of interferon sICAM-1 levels rebounded to initial values. Conclusions. In our study IFN therapy seemed to be able to determine a transient reduction of sICAM levels that disappeared after drug suspension.

Original languageEnglish
Pages (from-to)66-69
Number of pages4
JournalEuropean Journal of Laboratory Medicine
Volume5
Issue number2
Publication statusPublished - 1997

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Soluble intercellular adhesion molecule-1 in patients with chronic hepatitis C treated with interferon'. Together they form a unique fingerprint.

Cite this